Autopsy report · NCT01681797

Fluorescence Angiography: Planning and Monitoring of Perforator Flaps

“The study was stopped due to lack of inclusion”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 27 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University Hospital, Grenoble

Sponsor type

University, hospital or other

Conditions

Reconstructive Surgery

Interventions

Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)

Participants

27

Sites

1

Countries

France

Trials that died the same way

• Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen
  “The study was stopped due to lack of inclusions” (99% match in meaning)
• New Prophylactic Maneuver: the "Pushing" Maneuver, Aiming to Reduce the Risk for Shoulder Dystocia
  “the study stopped due to the lack of inclusion.” (93% match in meaning)
• Oxygen Therapy in Cystic Fibrosis
  “lack of inclusion in the study” (84% match in meaning)
• Bioavailability of Voriconazole
  “no eligible patients; study stopped without inclusion” (80% match in meaning)
• Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy
  “Study was halted for lack of accrual” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.